Posts Tagged: biomarker

The Prognostic Significance of Gene Mutations in Myeloproliferative Neoplasms

Relevant gene mutations in MPN and their prognostic significance for primary myelofibrosis (PMF). Myeloproliferative neoplasms (MPN) are a group of blood cancers characterized by significant symptoms and a high risk of transformation into acute leukemia. MPN include (primary) myelofibrosis (PMF), essential thrombocythemia (ET) and polycythemia vera (PV), and affect around 13,000, 134,000 and 148,000 patients… Read article →


WT1 expression and NPM1 mutations as biomarkers for minimal residual disease (MRD) monitoring in AML patients

The AML Global Portal highlights the value of AML biomarkers WT1 expression and NPM1 mutation for MRD monitoring in AML patients The AML_Global_Portal is an evidence-based online resource committed to informing and educating health care providers about the latest cutting-edge advancements in acute myeloid leukemia (AML). The portal aims to help advance understanding and share… Read article →


QIAGEN’s companion diagnostic business highlighted in the Journal of Precision Medicine

A recent publication in the Journal of Precision Medicine highlights QIAGEN’s companion diagnostic business development and Modaplex platform. The July 2016 issue of the Journal_of_Precision_Medicine (JPM) features an article by Jessica Johnson called “Companion Diagnostics – a Burgeoning Market” (1). In this article, Johnson provides a brief account of the recent history of companion diagnostics… Read article →


ESMO guidelines committee update clinical recommendations for metastatic colorectal cancer

The European Society for Medical Oncology (ESMO ) is a leading European professional organization for medical oncology and is considered the reference society for oncology education and information. Comprised of more than 13,000 oncology professionals from over 130 countries, ESMO is a home for all oncology stakeholders, and connects professionals with diverse expertise and experience…. Read article →